15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston

2 April 2008. Related: Conference reports, Conference index, CROI 15 (Retrovirus) 2008.

Reports from the conference

This annual conference is one of the most important annual scientific meetings.

Abstracts for the meeting are online as soon as the conference opens, and many of the most important oral abstract sessions and overview sessions are posted as webcasts within a day or so. We encourage readers to go directly to the source for many of these sessions

http://www.retroconference.org

This issue includes reports on antiretrovirals and treatment strategies, prevention of mother to child transmission (PMTCT), hepatitis coinfection and oncology:

• Atazanavir/r vs lopinavir/r in treatment-naive patients: 48 week results

• Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality

• Restarting treatment after an interruption reduces the risk of serious events but CD4 recovery falls short of baseline levels

• Very low rate of MTCT in women on HAART in UK and Ireland who achieve viral suppression

• Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort

• Maternal and infant outcomes from the DREAM programme

• Nevirapine-resistant HIV present in the latent reservoir following single-dose nevirapine for MTCT prevention

• Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine

• Response to treatment after single dose NVP exposure in women

• Response to treatment after single dose NVP exposure in infants

• Other studies looking at birth outcomes

• Infant prophylaxis for postnatal transmission

• Antiretroviral drug concentrations in breast milk and breastfeeding infants

• Maternal breastfeeding prophylaxis

• Risk factors for breastfeeding transmission

• UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment

• MELD score predictive of pre-transplant mortality in HCV coinfected patients

• Does abacavir decrease SVR rates with HCV treatment?

• No effect of interferon maintenance therapy on fibrosis progression in non-responders

• Stem cell transplant from HLA-matched CCR5-delta 32 deleted donor suppresses viraemia in recipient for 8 months without HAART

• Risk factors for AIDS-defining and non AIDS-defining cancers

Further coverage will be included in subsequent issues of HTB.